Normal view MARC view ISBD view

Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.

Exaire, J E

Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. [electronic resource] - Journal of thrombosis and haemostasis : JTH Jan 2004 - 7-9 p. digital

Publication Type: Journal Article; Review

ISSN: 1538-7933

Standard No.: 10.1111/j.1538-7836.2004.00559.x doi

Subjects--Topical Terms:
Abciximab
Angioplasty, Balloon, Coronary--methods
Antibodies, Monoclonal--adverse effects
Cost-Benefit Analysis
Humans
Immunoglobulin Fab Fragments--adverse effects
Platelet Aggregation Inhibitors--adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors
Safety

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)